Clinical trial NCT04359147: The Role of Stress Neuromodulators in Decision Making Under Risk and Selective Attention to Threat
Official title: The Role of Stress Neuromodulators in Decision Making Under Risk
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Yohimbine
Hydrocortisone
Yohimbine + Hydrocortisone
Placebo
Lead sponsor: Charite University, Berlin, Germany
Sponsor class: OTHER
First posted: 2020-04-24
Enrollment: 167
Sex: MALE
Minimum age (years): 18
Maximum age (years): 35
Standard ages: ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: BASIC_SCIENCE

Brief summary: Incidental affective states, i.e., affective states can influence decision making and selective attention to threatening information. Acute stress is such an affective state and is a powerful contextual modulator of decision-making processes and selective attention to threat. In terms of physiological and neurohormonal changes, the stress response has been well characterized: Exposure to stress elicits an array of autonomic, endocrine, and behavioral responses. The physiological stress response is mediated by the hypothalamic-pituitary-adrenal (HPA) axis and the locus coeruleus noradrenergic (LC-NA) system with cortisol and norepinephrine (NE) as their end products. There is compelling evidence that the stress hormones cortisol and NE influence cognitive processes. However, only very few studies so far used pharmacological approaches to specify the role of stress neuromodulators on decision making and selective attention to threat and these studies are hardly comparable due to differences in the experimental design, e.g., the decision making task used. Furthermore, the neural underpinnings of stress effects on decision making and selective attention to threat are uninvestigated so far. The aim of the proposed project is to clarify the role of the major stress neuromodulators, NE and cortisol, in their contribution to different processes related to decision making under risk and selective attention to threat. To this end, combined precise pharmacological stimulation, behavioral modeling, and fMRI methods will be applied to systematically disentangle the effects of stress hormones on risk attitudes and loss aversion as well as their relation to neural correlates of processing subjective value and risk. Using pharmacological manipulation, the influence of noradrenergic and glucocorticoid activity on decision making under risk at the behavioral, computational, and neural level will be investigated. In addition, the influence of noradrenergic and glucocorticoid activity on selective attention to threat at the behavioural and neural level using a dot-probe paradigm with fearful and neutral faces will be examined. Participants are randomly assigned to one of four groups: (A) yohimbine, (B) hydrocortisone, (C) yohimbine and hydrocortisone, or (D) placebo.


Eligibility criteria: Inclusion Criteria:

* Right-handed
* High-school diploma

Exclusion Criteria:

* Former and present DSM-5 axis I disorders according to the Structured Clinical Interview for DSM (SCID)
* Permanent medication of any kind
* Medical conditions associated with adrenal dysfunction or well-known impact on HPA activity or cognitive function
* Steroid use

Primary outcomes:
measure: Risk and loss-aversion, choice consistency
timeFrame: 45 minutes
measure: Patch-leaving times
timeFrame: 45 minutes
measure: Attentional bias to fearful faces
timeFrame: 12 minutes
measure: Blood-oxygen-level-dependent (BOLD) response
timeFrame: 45 + 12 minutes
Secondary outcomes:
measure: Salivary cortisol
timeFrame: 3 hours
measure: Salivary alpha amylase
timeFrame: 3 hours
measure: Systolic and diastolic blood pressure
timeFrame: 3 hours
measure: Heart rate
timeFrame: 3 hours
Other outcomes:
Locations:
city: Berlin
country: Germany
facility: Charite University
Study officials:
References: